The aim of the EMPEROR-Reduced, as well as the EMPEROR-Preserved studies is to investigate the safety and efficacy of empagliflozin versus placebo on top of guideline-directed medical therapy in patients with heart failure and either reduced ejection fraction or preserved ejection fraction.
This study evaluates the following outcome measures:
Please click the "Continue Session" button below to continue using the website. To end your session please click the "End Session" button below. After 5 minutes of inactivity your session will be terminated and you will be required to log in again.